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doi:10.101Unrelated Donor Reduced-Intensity Allogeneic
Hematopoietic Stem Cell Transplantation for Relapsed
and Refractory Hodgkin Lymphoma
Marcel P. Devetten,1 Parameswaran N. Hari,2 Jeanette Carreras,2 Brent R. Logan,2
Koen van Besien,3 Christopher N. Bredeson,4 Cesar O. Freytes,5 Robert Peter Gale,6
John Gibson,7 Sergio A. Giralt,8 Steven C. Goldstein,9 Vikas Gupta,10 David I. Marks,11
Richard T. Maziarz,12 Julie M. Vose,1 Hillard M. Lazarus,13 Paolo Anderlini8Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refrac-
tory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-
intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the
outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL
between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research
(CIBMTR). Patients were heavily pretreated, including autologous HCT in 89%. With a median follow-up
of 25 months, the probability of TRM at day 100 and 2 years was 15% (95% confidence interval [CI] 10%-
21%) and 33% (95%CI 25%-41%), respectively. The probabilities of progression free survival (PFS) and overall
survival (OS) were 30% and 56% at 1 year and 20% and 37% at 2 years. The presence of extranodal disease
and the Karnofsky Performance Scale (KPS)\90 were significant risk factors for TRM, PFS, and OS, whereas
chemosensitivity at transplantation was not. Dose intensity of the conditioning regimen (RIC versus NST) did
not impact outcomes. Unrelated donor HCTwith RIC/NST can salvage some patients with relapsed/refrac-
tory HL, but relapse remains a common reason for treatment failure. Clinical studies should be aimed at
reducing the incidence of acute graft-versus-host disease (GVHD) and relapse.
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Although most patients with Hodgkin lymphoma
(HL) can expect long-term survival with standard che-
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6/j.bbmt.2008.11.011less favorable for patients with relapsed and/or refrac-
tory disease [1]. Most patients with relapsed disease are
treated with high-dose chemotherapy and autologous
stem cell rescue, based on the results of studies show-
ing durable responses in 40% to 50% of patients with
relapsed HL and in 25% to 40% of patients with
refractory HL [2-5]. Therapeutic options for patients
relapsing after high-dose chemotherapy are limited,
and generally noncurative.
Myeloablative allogeneic hematopoietic cell trans-
plantation (HCT) derives its benefit from both the
pretransplant conditioning regimen and a posttrans-
plant immune-mediated graft-versus-malignancy
effect. Although earlier studies suggested the existence
of a graft-versus-HL effect, the high transplant-related
mortality (TRM) associated with the use of myeloabla-
tive conditioning offset any potential benefit on
survival [6-9]. Reduced-intensity conditioning (RIC)
regimens have been developed in an attempt to
decrease the mortality caused by traditional high-
dose chemotherapy and radiation conditioning regi-
mens [10]. A variety of conditioning regimens, ranging
in intensity from immune suppressive and truly109
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introduced into practice. Such regimens have allowed
allogeneic HCT in persons who are traditionally not
considered for myeloablative transplant regimens
because of age or comorbidities [11-13]. In addition,
reduced-intensity allogeneic HCT is increasingly
used as a salvage strategy for patients who relapse after
previous high-dose chemotherapy with autologous
stem cell rescue [14].
Data on the use of RIC and nonmyeloablative stem
cell transplantation (NST) for patients with relapsed
and refractoryHL are starting to emerge. Several small
single-institution retrospective trials have reported
low early TRM and encouraging progression-free sur-
vival (PFS) data, although with limited follow-up
[15,16]. Data from 3 prospective trials have been re-
ported recently [17-19]. All 3 studies reported on the
outcomes of patients with relapsed and/or refractory
HL (in many cases after previous high-dose chemo-
therapy) undergoing allogeneic HCT with a condi-
tioning regimen of fludarabine and melphalan. These
studies confirmed a low day 100 TRM (ranging from
4% to 12.5%) with a projected PFS of 32% to 39%
at 2-4 years. Disease relapse/progression continued
to be the major reason for treatment failure in all 3
publications. A retrospective analysis by the Lym-
phoma Working Party of the European Group for
Blood and Marrow Transplantation (EBMT) compar-
ing RIC outcomes with outcomes after standard mye-
loablative conditioning also showed a reduction in day
100 TRM (15%with RIC versus 28%with myeloabla-
tive conditioning, P 5 .003) and a projected 3-year
PFS of 19% after RIC HCT [20].
Only a minority of patients in the previously cited
studies underwent transplantation with an unrelated
donor graft. Recent studies support the notion that
the results of unrelated donor HCT are comparable
to sibling grafts, if HLA matching at the allele level
is employed for unrelated donor selection [21,22].
We therefore analyzed the clinical outcomes of 143
patients undergoing unrelated donor HCT with
a RIC/NST conditioning regimen for relapsed and
refractory HL.PATIENTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP), that comprises a voluntary working group of
more than 450 transplant centers worldwide that con-
tribute detailed data on consecutive allogeneic and
autologous transplants to a Statistical Center at the
Health Policy Institute of the Medical College ofWisconsin in Milwaukee or the NMDP Coordinating
Center in Minneapolis. Participating centers are
required to report all consecutive transplants; compli-
ance is monitored by on-site audits. Subjects are
followed longitudinally, with yearly follow-up.
Computerized checks for errors, physicians’ review
of submitted data, and on-site audits of participating
centers ensure data quality. Observational studies con-
ducted by the CIBMTR are done with a waiver of
informed consent and in compliance with HIPAA reg-
ulations as determined by the institutional review
board and the Privacy Officer of the Medical College
of Wisconsin.
The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,
age, sex, pretransplant disease stage, and chemother-
apy responsiveness, date of diagnosis, graft type
(bone marrow- and/or blood-derived stem cells),
high-dose conditioning regimen, posttransplant
disease progression and survival, development of
a new malignancy, and cause of death. Requests for
data on progression or death for registered patients
are at 6-month intervals. All CIBMTR teams contrib-
ute registration data. Research data are collected on
a subset of registered patients selected using aweighted
randomization scheme and include detailed disease,
and pre- and posttransplant clinical information.
Definitions of RIC and Nonmyeloablative
Conditioning Regimens
Conditioning regimens were categorized as
reduced intensity or nonmyeloablative using consen-
sus criteria proposed by the Regimen-Related Toxicity
Working Committee of the CIBMTR. Regimens
employing total-body irradiation (TBI) \500 cGy,
busulfan doses #9 mg/kg, or melphalan doses #150
mg/m2 were categorized as reduced intensity. Regi-
mens using fludarabine without busulfan and/or mel-
phalan and regimens using TBI doses of 200 cGy
(with or without fludarabine) were categorized as non-
myeloablative. Regimens that did not fit these criteria
were assigned by the authors based on recommenda-
tions of the Regimen-Related Toxicity Working
Committee. This consensus definition reflects the
practice of a large segment of the transplant commu-
nity and has also been proposed and used by others
[23,24].
Patients
There were 143 patients undergoing an unrelated
donor HCT between 1999 and 2004 with RIC/NST
conditioning for relapsed or refractory HL identified
from the CIBMTR database. Patients undergoing
a cord blood transplant (n 5 4), those undergoing
planned tandem (autologous followed by RIC/NST
allogeneic) HCT (n 5 3), and those who received
Table 1. Variables Tested in Cox Proportional Hazards
Regression Models
Patient-related variables:
Age at transplant: 13-20 versus 21-30 versus
31-40 versus 41-50 versus 51-60 years
Karnofsky performance status at transplant: $90% versus <90%
Disease related:
Disease status and chemosensitivity at transplant: PIF-sensitive versus PIF
resistant versus REL sensistive versus REL resistant versus REL untreated/
unknown
Extranodal involvement prior to transplant: yes vs no
LDH concentration at transplant: normal versus abnormal versus unknown
Treatment related:
Time from autologous to allogeneic transplant: <12 versus 12-24 versus$24
months
Donor type: HLA-matched unrelated versus HLA-mismatched unrelated
Donor-recipient gender match: F-M versus others
Donor/recipient CMV status: 2/2 versus others
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malignancy were excluded from analysis. HLA
compatibility of donors and recipients was docu-
mented at low resolution (antigen level) for HLA A
and B antigens and at high resolution (allele level) for
the HLA-DRB1 allele. Chemosensitive disease was
defined as a 50% reduction in the sum of the bidimen-
sional diameter of all disease sites with no new sites of
disease.
Study Endpoints
Outcomes analyzed included TRM, progression,
PFS, and overall survival (OS). TRM was defined as
death within 28 days posttransplant or death without
lymphoma progression. Subjects with lymphoma
progression were censored at the time of progression
and a cumulative incidence estimate was derived with
progression or relapse as the competing risk. Progres-
sion was defined as progressive lymphoma posttrans-
plant ($28 days) or lymphoma recurrence. It could
follow a period of ‘‘stable’’ disease posttransplant, or
a partial (PR) or complete remission (CR). Progression
represents new or larger areas of lymphoma ($25%
increase in largest diameter) compared to the best
posttransplant lymphoma state. Progression was sum-
marized by the cumulative incidence estimate with
TRM as the competing risk. For PFS, subjects were
considered treatment failures at the time of lymphoma
progression or death from any cause. Subjects alive
without evidence of lymphoma progression were
censored at last follow-up and the PFS event was sum-
marized by a survival curve. The OS interval variable
was defined as time from the date of transplant to the
date of death or last contact and summarized by a sur-
vival curve.
Statistical Analysis
Univariate probabilities of developing TRM and
lymphoma relapse/progression were calculated using
cumulative incidence curves to accommodate
corresponding competing risks [25]. Probabilities of
100-day OS and PFS were calculated using a Kaplan-
Meier estimator [26]. Confidence intervals (CIs) were
calculated with a log-transformation.
Cox proportional hazards model was used to iden-
tify risk factors associated with outcomes. A stepwise
forward selection multivariate model was built to iden-
tify covariates that influenced outcomes. Any covariate
with a P-value #.05 was considered significant. The
proportionality assumption for Cox regression was
tested by adding a time-dependent covariate for each
risk factor and each outcome. Tests indicated that all
variables met the proportional hazards assumption.
Results were expressed as relative risks (RR) or the
relative rate of occurrence of the event. The following
variables were considered in multivariate analyses: ageat transplant, Karnofsky Performance Status (KPS) at
transplant, disease status, and chemosensitivity at
transplant, extranodal involvement prior to transplant,
serum lactate dehydrogenase (LDH) concentration at
transplant, time from autologous HCT to allogeneic
HCT, donor type (HLA matched versus HLA
mismatched), donor-recipient gender match (female
donor into male recipient versus all other combina-
tions) and donor-recipient cytomegalovirus (CMV)
status (both donor and recipient CMV seronegative
versus all other combinations) (Table 1). Analyses
were performed using SAS software, version 8.2 (SAS
Institute, Cary, NC).RESULTS
Patient, Disease-, and Transplant-Related
Variables
Patient, disease, and transplant characteristics are
described in Table 2. Ninety-four patients (66%)
received RIC regimens, whereas 49 (34%) patients re-
ceived nonmyeloablative conditioning regimen (Table
3). As expected, this was a group of heavily pretreated
patients. Ninety-six percent of patients had been
treated with at least 3 previous chemotherapy regi-
mens, and the majority of patients (89%) had received
a prior autologous HCT. In addition, 47% had disease
characterized as chemoresistant at the time of alloge-
neic HCT, 50% had extranodal involvement prior to
transplant, and 32% had a Karnofsky performance sta-
tus\90 preallogeneic transplant. Twenty-three per-
cent received a graft from an HLA mismatched
unrelated donor; however, we do not have the results
of high-resolution HLA typing for class I HLA anti-
gens, and thus the number of patients receiving an
allele mismatched product might be substantially
higher. Most patients (73%) received a peripheral
blood stem cell graft and were transplanted after
Table 2. Patient-, Disease-, and Transplant Characteristics
Variable N Eval N (%)
Number of patients 143
Age, median (range), years 143 30 (13-53)
Male sex 143 82 (57)
Karnofsky score pretransplant 119
<90 38 (32)
$90 81 (68)
Histology 143
Nodular sclerosis 126 (88)
Mixed cellularity 8 ( 6)
Otherb 9 ( 6)
Prior radiation therapy 143
Yes 38 (27)
No 105 (73)
Number of prior chemotherapy regimens 143
<3 5 ( 3)
$3 137 (96)
Unknown 1 ( 1)
Chemosensitivity of disease at transplant 141
Sensitive 62 (44)
Resistant 67 (47)
Untreated 8 ( 6)
Not evaluable /Unknown 4 ( 3)
Extranodal involvement prior to transplant 141
Yes 70 (50)
No 71 (50)
LDH concentration at transplant 143
Normal 97 (68)
Abnormal 39 (27)
Unknown 7 ( 5)
Prior autologous HCT 143
Yes 127 (89)
No 16 (11)
Time from autologous to allogeneic transplant,
median (range), months
127 19 (2-156)
Donor/recipient CMV status 142
2/2 54 (38)
Others 88 (62)
Donor leukocyte infusion 143
Yes 21 (15)
No 122 (85)
Bone marrow involvement at diagnosis 143
Yes 9 ( 6)
No 134 (94)
Donor type 143
HLA-matched unrelated 110 (77)
HLA-mismatched unrelated 33 (23)
Donor-recipient gender match 143
F-M 30 (21)
Others 113 (79)
Source of stem cells 143
Bone marrow 39 (27)
Peripheral blood 104 (73)
Year of transplant 143
1999-2000 17 (12)
2001-2002 42 (29)
2003-2004 143 84 (59)
GVHD prophylaxis 143
CsA + MTX ± other 23 (16)
CsA ± other 48 (34)
FK506 ± other 26 (18)
FK506 + MTX ± other 43 (30)
T cell depletion ± other 2 ( 1)
Given, not specified 1 ( 1)
Mycophenolate mofetil as GVHD prophylaxis 143
Yes 55 (38)
No 88 (62)
CsA, cyclosporine; MTX, methotexate; GVHD, graft-versus-host
disease; LDH, lactate dehydrogenase; HCT, hematopoietic cell trans-
plantation; CMV, cytomegalovirus.
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months.
TRM, Progression/Relapse, and Survival
Cumulative incidences for TRM, progression/
relapse, acute and chronic graft-versus-host disease
(aGVHD, cGVHD) and Kaplan Meier curves for
PFS and OS are shown in Figure 1. Cumulative inci-
dence of TRM following unrelated donor RIC/NST
for relapsed or refractory HD was 15% at 100 days
(95% CI 10%-21%), 30% (95% CI 22%-37%) at 1
year and 33% (95% CI 25%-41%) at 2 years
(Figure 1a). In multivariate analysis lower KPS at
transplantation (relative risk [RR] 3.05 for KPS\90,
P \ .001) and the presence of extranodal disease at
transplantation (RR 2.36, P 5 .007) were associated
with an increased risk of TRM (Table 4).
The cumulative incidence of progression/relapse
in the RIC/NST group was 40% at 1 year (95% CI
32%-49%) and 47% at 2 years (95% CI 39%-56%)
(Figure 1a). No variables were associated with a higher
risk of relapse/progression (Table 4). The probability
of PFS at 1 year was 30% (95% CI 23%-38%) and at
2 years 20% (95%CI 13%-27%). In multivariate anal-
ysis factors with a significant effect on PFSwere a lower
KPS (RR 2.19 for KPS\90, P\ .001) and extranodal
involvement at transplantation (RR 1.73, P 5 .006)
(Table 4).
The probability of survival after RIC/NST was
56% (95% CI 48%-64%) at 1 year and 37% (95%
CI 29%-46%) at 2 years (Figure 1b). In multivariate
analysis factors significantly affecting survival were
a lower KPS (RR 2.33 for KPS\90, P\ .001), pres-
ence of extranodal disease at diagnosis (RR 2.11, P 5
.001), and abnormal serum LDH concentration (RR
1.86, P 5 .008) (Table 4).
RIC versus NST
To separate the effects of differing intensity of
conditioning regimens, we analyzed the effects of
RIC and nonmyeloablative conditioning separately in
a multivariate analysis. There were no significant
differences between RIC andNST on the primary out-
comes for TRM, progression/relapse, PFS, and OS.
The 2 groups were combined for the final analysis to
increase the overall power of the study.
Acute GVHD and cGVHD and Effect of
Chemosensitivity
RIC/NST conditioning regimens were associated
with a high incidence of aGVHD and cGVHD. The
probability of grade 2-4 aGVHD by day 100 was
60% (95% CI 51%-69%) (Figure 1c), and the proba-
bility of cGVHD was 66% at 1 year (95% CI 58%-
74%) and 68% at 2 years (95% CI 60%-76%)
(Figure 1d).
Table 3. Conditioning Regimens Used for RIC/NST
Regimen N (%)
TBI dose <500 cGy single dose or <800 cCy fractionated 8 ( 6)
Melphalan dose #150 mg/m2 50 (34)
Busulfan dose #9 mg/kg 36 (25)
TBI dose 5 200 cGy 25 (17)
Fludarabine + cyclophosphamide 23 (16)
Fludarabine + Thiotepa + ATG 1 ( 1)
ATG indicates antithymocyte globulin; RIC, reduced-intensity condition-
ing; NST, nonmyeloablative.
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therapy immediately prior to transplant was not
identified as a characteristic with a significant effect
on PFS or OS. Because prior studies have identified
chemosensitivity as an important predictor for survival
we performed an additional analysis for the effect of
chemosensitivity on PFS and OS. The Kaplan-Meier
curves for PFS and OS for chemosensitive and chemo-
resistant patients are shown in Figure 2.Causes of Death
Causes of death are listed in Table 5. Relapse/pro-
gression was the main cause of death after RIC/NST
transplantation. Infection was the second most com-
mon cause of death, whereas organ failure and intersti-
tial pneumonitis were rare after RIC/NST.C
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Figure 1. TRM, relapse/progression (a), PFS, andOS (b), aGVHD (c), and cGVDISCUSSION
Treatment options for patients with relapsed or
refractory HL, in particular, patients who relapse after
previous high-dose chemotherapy treatment, remain
limited. The use of allogeneic HCT with a RIC/
NST conditioning regimen has theoretic appeal for
those patients, but reported outcome data are sparse
and mostly limited to patients receiving matched sib-
ling grafts. Our study represents the largest group of
unrelated donor HCT recipients with RIC/NST for
relapsed/refractory HL analyzed to date, and almost
all patients in our analysis underwent RIC/NST
HCT as a salvage strategy after previously failed
high-dose chemotherapy with autologous stem cell
rescue. This study confirms the feasibility of RIC/
NST unrelated donor allogeneic HCT and shows
that approximately 20% of patients with multiply
relapsed or refractory HL may experience prolonged
PFS with a projected 2-year OS of 37%. Not unex-
pectedly, relapse/progression remains a significant
problem in this group of heavily pretreated patients.
Our survival results are comparable with previ-
ously published data. The recently published EBMT
experience reports a 3-year PFS of 19% (95% CI
11%-28%), with a 3-year OS of 35% (95% CI 24%-
45%) [20]. Slightly better survival results have been
reported in the 3 prospective studies. Peggs et al.
[17] reported a 4-year actuarial PFS of 22.6% andYears
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Table 4. Multivariate Analyses Comparing TRM, Pro-
gression/Relapse, PFS, and OS for Unrelated Donor NST/RIC
HCT for Relapsed/Refractory HD
Variables N Relative Risk (95% CI) P-Value
TRM:
Karnofsky score pretransplant
$90% 79 1.00
<90% 37 3.05 (1.58-5.87) <.001
Extranodal involvement
No 71 1.00
Yes 68 2.36 (1.26-4.41) .007
Progression/relapse: N/A
No significant variables
PFS:
Karnofsky score pretransplant
$90% 79 1.00
<90% 37 2.19 (1.42-3.39) <.001
Extranodal involvement
No 71 1.00
Yes 68 1.73 (1.17-2.55) .006
OS:
Karnofsky score pretransplant
$90% 74 1.00
<90% 36 2.33 (1.45-3.75) <.001
Extranodal involvement
No 65 1.00
Yes 69 2.11 (1.34-3.31) .001
LDH concentration
Normal 96 1.00
Abnormal 38 1.86 (1.18-2.93) .008
CI indicates confidence interval; NA, not applicable; LDH, lactate dehy-
drogenase; PFS, progression-free survival; OS, overall survival; TRM,
treatment-related mortality..
114 Biol Blood Marrow Transplant 15:109-117, 2009M. P. Devetten et al.OS of 45% for recipients of an unrelated donor graft in
their prospective study. PFS at 2 years was 32%6 10%
in the Spanish prospective trial, but only 2 of 40 pa-
tients in this study received an unrelated donor graft
[18]. In the M.D. Anderson study, 2-year PFS was
32% (95%CI 20%-45%), and no difference was noted
between recipients of related (n5 25) and unrelated (n
5 33) donor grafts [19]. The apparent survival differ-
ence between the prospective trials and the registry
data is not unexpected, and probably explained by
the carefully controlled eligibility criteria and thera-
peutic conditions that apply to prospective trials.
RIC regimens are designed to limit TRM, and
several studies have reported low TRM after reduced
intensity HCT. The day-100 TRM of 15% (95% CI
10%-21%) and TRM of 30% (95% CI 22%-37%) at
1 year and 33% (95% CI 25%-41%) at 2 years there-
fore seem somewhat disappointing. In the EBMT
study cumulative TRM was 15% at 3 months (95%
CI 9%-24%), 23% at 1 year (95% CI 15%-34%),
and 24% at 3 years (95% CI 16%-35%) [20]. This
study, however, included predominantly matched sib-
ling donors (86.5%), and fewer patients had failed
a previous autologous HCT (61.8%). Much lower cu-
mulative incidences of TRM were reported in the UK
study (4.1% at 100 days and 16.3% at 2 years) and the
Spanish study (12.5% at 100 days and 25% at 3 years)
[17,18]. However, in theUK study TRM at 2 years wassignificantly higher with an unrelated donor HCT
than when a matched sibling donor was used (34.1%
[16.5-70.3] versus 7.2% [1.9-27.5], P 5 .02). The
most favorable TRMdata come from theM.D. Ander-
son patient cohort, where day 100 TRMwas 7% (95%
CI 2%-12%) and 2-year TRMwas 15% (95% CI 8%-
28%), with no significant difference noted between
related and unrelated graft recipients [19]. A compari-
son of TRM between studies is difficult without
adjustment for some of the known risk factors for
TRM after allogeneicHCT; of note is that the patients
in our study represented a poor-risk group, including
KPS\90 for one-third of all RIC/NST recipients.
A high incidence of aGVHD was noted in our
study, with a 60% probability of grade 2-4 aGVHD
at 100 days (95% CI 51%-69%). For comparison,
the incidence of grade 2-4 aGVHD in the M.D.
Anderson unrelated donor cohort was 39% (95% CI
26%-60%) [19]. The UK study does not allow for
a meaningful comparison of aGVHD incidence, as in
vivo T cell depletion with alemtuzumab was an inte-
gral part of the conditioning regimen on that protocol.
Any discussion of the differences in TRM and
aGVHD incidence between our study and some of
the referenced trials remains necessarily speculative.
The extent of HLA matching at the allele level was
not available for most of the patients in our database,
precluding an analysis of the effect of allele matching
on outcomes, in particular, incidence of GVHD.
The presence of a significant number of HLA mis-
matched donor-recipient pairs (23%), even at this
low level of HLA matching, could explain the rela-
tively high incidence of aGVHD in this study.
The primary causes of death of nonrelapse mortal-
ity (NRM) in our study were infectious in 22% and
GVHD in 9% of all deaths. One could hypothesize
that the high incidence of aGVHD in this study can
at least partially explain the significant TRM, as infec-
tious complications and occurrence of GVHD are of-
ten related. This would suggest that attempts to reduce
the incidence of aGVHD could result in more favor-
able TRM. In support of this hypothesis are the find-
ings by Peggs et al. [27] that the use of alemtuzumab
in the conditioning regimen resulted in lower inci-
dences of NRM and aGVHD and cGVHD without
affecting the incidence of relapse/progression after
matched sibling RIC HCT.
We were not able to show a significant effect of the
intensity of the conditioning regimen (nonmyeloabla-
tive versus reduced intensity) on TRMor survival. Our
study had only very limited power to detect differences
between these 2 transplant approaches, and great care
should therefore be used in interpreting these results.
Anderlini et al. [16] have suggested a benefit of RIC
with fludarabine and melphalan over nonmyeloabla-
tive conditioning with fludarabine and cyclophospha-
mide. Because the current study included a wide
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Figure 2. Effect of chemosensitivity at the time of transplantation on PFS (a) and OS (b) after unrelated donor RIC/NST HCT for relapsed/refractory
HL.
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not very suitable for a direct comparison between the
various regimens. In addition, retrospective studies
cannot control for potential bias resulting in the
selection of 1 conditioning regimen over another for
any particular patient.
Our study did not show an effect of pretransplant
chemosensitivity on survival in the multivariate analy-
sis. The reasons for this discrepancy between our
findings and previously reported effects of chemosen-
sitivity remain speculative. Selection bias might have
played a role; the reason for administration of a RIC/
NST conditioning is not collected by the CIBMTR,
and patients with highly refractory disease might
therefore preferentially have been treated with more
intense conditioning regimens or might have been
denied RIC/NST procedures altogether. The rela-
tively recent introduction of PET scanning mighthave resulted in more accurate but altered definitions
of remission status at the time of transplantation and
precludes comparison between studies. Finally, prog-
nostic differences between the patients in our study
and in other studies may explain the lack of effect
attributable to chemosensitivity.
In summary, our study shows that some patients
with highly refractory/relapsed HL can be salvaged
with the use of unrelated donor RIC/NST HCT.
The results of our and other recently published analy-
ses establish the feasibility of this procedure for
patients with relapsed or refractory HL. However,
both in our and in other studies relapse/progression
continues to be the most common cause of treatment
failure, and long-term prognosis continues to be
largely determined by patient-related (KPS) and dis-
ease-related (extranodal disease) factors rather than
by the choice of conditioning approach. These data
Table 5. Causes of Death of Unrelated Donor NST/RIC HCT
for Relapsed/Refractory HD
Causes of Death N Eval N (%)
Number of patients 88
Primary disease 39 (44)
GVHD 8 ( 9)
IpN 5 ( 6)
Infection 19 (22)
Organ Failure 11 (13)
Other/Unknown* 6 ( 6)
GVHD indicates graft-versus-host-disease; NST/RIC, nonmyeloablative
and reduced-intensity conditioning.
*Other includes: PTLD (n5 1), hemorrhage (n5 1), accidental (n5 1),
neuropathy (n 5 1), unknown (n 5 2).
116 Biol Blood Marrow Transplant 15:109-117, 2009M. P. Devetten et al.support the notion that careful patient selection
remains the single most important factor to improve
outcomes from RIC/NST unrelated donor HCT for
this indication. In addition, approaches to further
reduce the incidence of GVHD and TRM after RIC/
NST HCT should result in more favorable outcomes.
This should foremost include HLA matching at the
allele level, and could also include the addition of
alemtuzumab to the conditioning regimen, the use of
umbilical cord blood grafts, or the use of a tandem
approach (high-dose chemotherapy with autologous
stem cell rescue followed by an allogeneic HCT with
nonmyeloablative conditioning) in high-risk patients
[27-29]. Development of multi-institutional clinical
trials to examine these options is highly desirable.ACKNOWLEDGMENTS
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